We are live on
!
Find out more
FFVM
Founders Fund V Management Portfolio holdings
AUM
$2.16M
1-Year Est. Return
77.37%
This Fund
S&P 500
This Quarter
Est. Return
-27.43%
1 Year Est. Return
+77.37%
3 Year Est. Return
+859.57%
5 Year Est. Return
-74.2%
10 Year Est. Return
–
AUM
$1.07M
AUM Growth
-$614K
(-36%)
Cap. Flow
+$49.3K
Cap. Flow
% of AUM
4.61%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
4
New
1
Increased
–
Reduced
–
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rafael Holdings
RFL
|
+$333K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CYTH
Cyclo Therapeutics, Inc. Common Stock
CYTH
|
+$284K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 65.6% |
| 2 | Real Estate | 29.62% |
| 3 | Healthcare | 4.78% |
Similar funds
NA
FFVM
IVSFI
MI
AICPI
FFVM
SNN
AC
Founders Fund V Management's Q1 2025 Portfolio in Review
As of Q1 2025, Founders Fund V Management held 4 positions worth $1.07M, down 36% from $1.68M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Founders Fund V Management deployed $49.3K of net new capital in Q1 2025, opening 1 new position. Its largest new stake was Rafael Holdings: 171,823 shares worth $317K.
By sector, the portfolio is most concentrated in Technology at 66% of assets, down from 80% a quarter earlier, followed by Real Estate and Healthcare.
On the sell side, the most notable exit was Cyclo Therapeutics, Inc. Common Stock, an estimated $284K sold.
- Founders Fund V Management's largest Q1 2025 buy was Rafael Holdings: 171,823 shares worth $317K.
- Founders Fund V Management fully exited Cyclo Therapeutics, Inc. Common Stock in Q1 2025, selling an estimated $284K.
- Founders Fund V Management's ten largest holdings make up 100% of its $1.07M portfolio in Q1 2025.
- Founders Fund V Management opened 1 new position and closed 1 in Q1 2025.
- Founders Fund V Management's portfolio value fell 36% quarter-over-quarter to $1.07M.
Based on Founders Fund V Management's 13F filing for Q1 2025, filed 15 May 2025.